Effect of Indomethacin on the Progression of Alzheimer's Disease
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Effect of Indomethacin on the Progression of Alzheimer's Disease|
- Score on the Cognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months.
- Score on the Noncognitive subscale of the Alzheimer’s Disease Assessment Scale at 12 months
- Score on the Clinician Interview-Based Impression of Change with caregiver input at 12 months
- Score on the Mini-Mental State Examination at 12 months
- Score on the Neuropsychiatric Inventory at 12 months
- Score on the The Interview for Deterioration in Daily living activities in Dementia at 12 months
- The occurrence of adverse events during 12 months of treatment
|Study Start Date:||May 2000|
|Estimated Study Completion Date:||August 2005|
Previous research indicates that inflammation plays a role in the pathogenesis of Alzheimer’s disease (AD), and nonsteroidal anti-inflammatory drugs (NSAIDs) may retard the progression of the disease.
Comparison(s): Cognitive decline of patients with mild to moderate AD receiving the NSAID indomethacin, compared to cognitive decline of patients with mild to moderate AD receiving placebo, during a one-year period.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00432081
|Arnhem, Netherlands, 6800 TA|
|Radboud University Medical Center|
|Nijmegen, Netherlands, 6500 HB|
|Principal Investigator:||Rene WM Jansen, MD, PhD||Radboud University Medical Center Nijmegen|
|Principal Investigator:||Berry PH Kremer, MD, PhD||Radboud University Medical Center Nijmegen|
|Study Director:||Danielle De Jong, MD||Radboud University Medical Center Nijmegen|